immunology

Sanofi to Acquire Blueprint Medicines

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology.

US Merck Snaps up Prometheus Biosciences for $10.8 Billion

Shares of Prometheus Biosciences soared on news that US drugs major Merck will acquire the company in an all-cash deal valued at roughly $200 per share, or $10.8 billion.

Bayer Plans to Scale Back Women’s Health R&D

Ahead of a change in leadership at the top after the upcoming annual general meeting, in interviews with news agencies Bayer is dropping hints in dribbles about future plans for its healthcare business.

Pfizer Doubles Dublin Biologicals Capacity

Pfizer has announced plans to invest more than €1.2 billion at its site in Grange Castle, Dublin, Ireland, to double capacity for biological drug substances.

Sanofi and Ablynx Link on Nanobody Therapeutics

The Possibilities Of Peptides

Novartis Splits Pharmaceutical Division

Sanofi Appoints Dr. Yong-Jun Liu as Head of Global Research

AbbVie and Boehringer Collaborate on Immunology Drugs

Merck Extends Pact with Weizmann Institute

Sanofi and BioNTech Collaborate on Cancer

Crown Bioscience Opens Oncology Center in North Carolina

Sanofi Pasteur Acquires Worldwide License For Acne Vaccine, Treatment